OECD Book: Innovation in Pharmaceutical Biotechnology - Comparing National Innovation Systems at the Sectoral Level (link)

Paris, 10 Apr 2006

What are the specific characteristics of innovation in pharmaceutical biotechnology? How do biopharmaceutical innovation systems in OECD countries perform and which policies are suitable to foster performance?

This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries: Belgium, Finland, France, Germany, Japan, the Netherlands, Norway and Spain. The report summarises the results of in-depth studies, providing a comparative analysis of participating countries' performance in science and innovation in biopharmaceuticals. It highlights specific characteristics of the national biopharmaceutical innovation systems in terms of their international openness and the specific role of demand-side factors in the innovation process. Major systemic failures affecting the functioning of the biopharmaceutical innovation systems are identified. Based on rich evidence, the report draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.

This study forms part of a larger effort to compare innovation processes in different industry sectors and technological fields to provide policy guidance and to more fully elaborate the national innovation systems (NIS) approach to policy making.

Table of contents

Foreword

Executive Summary (English) - available for free download

Note de synthèse (French) - available for free download

  • Chapter 1. Introduction

  • Chapter 2. Summary of Country Studies:
    • Belgium
    • Finland
    • France
    • Germany
    • Japan
    • The Netherlands
    • Norway
    • Spain
Chapter 3. Comparison of Performance in National Biopharmaceutical Innovation Systems

Chapter 4. Openness of the Biopharmaceutical Innovation System

Chapter 5. Comparison of Selected Demand-side Factors

Chapter 6. Structure, Dynamics and Performance in National Biopharmaceutical Innovation Systems

Chapter 7. Systemic Imperfections in Biopharmaceutical Innovation Systems

Chapter 8. Policy Implications

The full volume can be browsed on the OECD Online Bookshop.

Further information

Organisation for Economic Co-operation and Development
http://www.oecd.org
Item source

Already registered?

Sign in now if you are already registered or a current subscriber. Or subscribe for unrestricted access to our digital editions and iPad and iPhone app.

Register to continue  

You've enjoyed reading five THE articles this month. Register now to get five more, or subscribe for unrestricted access.

Most Commented

  • Man measuring bar graphs with tape measure

An Elsevier analysis explores the viability of a ‘smarter and cheaper’ model

  • David Willetts

The former universities minister discusses the reforms that reshaped higher education and his first steps into academia

  • Man holding a box filled with work-related items

Refusal by John Allen to obey instruction from manager at Queen Mary University of London led to his sacking, tribunal rules

  • A black and white crowd scene with a few people highlighted

What are the key issues local union branches are dealing with, and how do they manage relationships with institutions in what many activists argue is an increasingly confrontational environment?

  • Muslim woman at graduation ceremony, Barbican, London

Sector called on to embrace faith-related concerns in intellectual debates